JPMorgan Chase & Co. Increases Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $18.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective upped by research analysts at JPMorgan Chase & Co. from $16.00 to $18.00 in a report released on Monday, Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential downside of 2.07% from the stock’s previous close.

Several other analysts have also weighed in on TEVA. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. UBS Group upped their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Wednesday, July 10th. Jefferies Financial Group increased their target price on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average target price of $19.33.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $18.38 on Monday. The firm has a market cap of $20.82 billion, a P/E ratio of -47.13, a P/E/G ratio of 1.29 and a beta of 0.88. The stock’s 50 day moving average is $18.01 and its 200 day moving average is $16.71. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. Teva Pharmaceutical Industries has a one year low of $8.06 and a one year high of $19.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The company had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. As a group, research analysts expect that Teva Pharmaceutical Industries will post 2.33 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now owns 45,060 shares in the company, valued at approximately $777,285. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sequoia Financial Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 0.7% in the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after acquiring an additional 805 shares during the period. Edmond DE Rothschild Holding S.A. boosted its position in shares of Teva Pharmaceutical Industries by 4.0% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company’s stock valued at $346,000 after acquiring an additional 947 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Teva Pharmaceutical Industries by 16.9% during the third quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock worth $137,000 after purchasing an additional 1,094 shares in the last quarter. Oppenheimer & Co. Inc. increased its position in shares of Teva Pharmaceutical Industries by 9.6% in the first quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock worth $191,000 after purchasing an additional 1,180 shares during the last quarter. Finally, QRG Capital Management Inc. lifted its position in Teva Pharmaceutical Industries by 0.8% during the second quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock valued at $2,355,000 after purchasing an additional 1,191 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.